Cargando…

RWD91 A Real-World Pharmacovigilance Study Using National Russian Database of Adverse Events of COVID-19-Related Drugs: Focus on Hydroxychloroquine

Detalles Bibliográficos
Autores principales:	Kolbin, A, Mishinova, SA, Syraeva, GI, Polushin, YS
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Inc. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232774/ http://dx.doi.org/10.1016/j.jval.2022.04.1615

Ejemplares similares

RWD61 Analysis of the National Database of the Russian Federation on the Safety of Medicines for Etiopathogenetic Treatment covid-19 in Clinical Practice (REAL-WORLD DATA; RWD)
por: Kolbin, A, et al.
Publicado: (2022)

Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin: An Analysis of the World Health Organization Pharmacovigilance Database
por: Nguyen, Lee S., et al.
Publicado: (2020)

POSC413 A Systematic Review of Real-World Clinical Practice Data in COVID-19: Non-Interventional Studies
por: Mishinova, S, et al.
Publicado: (2022)

Serious adverse drug reactions with hydroxychloroquine: a pharmacovigilance study in Vigibase®
por: Montastruc, Jean-Louis, et al.
Publicado: (2020)

Detecting medication errors associated with the use of beta-lactams in the Russian Pharmacovigilance database
por: Kuzmina, Anna V., et al.
Publicado: (2021)

RWD-Cockpit: Application for Quality Assessment of Real-world Data
por: Babrak, Lmar Marie, et al.
Publicado: (2022)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Adverse drug reactions associated with ivermectin use for COVID-19 reported in the World Health Organization's pharmacovigilance database
por: Campillo, Jeremy T., et al.
Publicado: (2022)

RWD-derived response in multiple myeloma
por: Xu, Tao, et al.
Publicado: (2023)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Adverse drug reactions of hydroxychloroquine: Analysis of French pre-pandemic SARS-CoV2 pharmacovigilance data
por: Grandvuillemin, Aurélie, et al.
Publicado: (2020)

An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19
por: Luo, Min, et al.
Publicado: (2022)

Real-World Outcomes in Patients with Metastatic Colorectal Cancer in Spain: The RWD-ACROSS Study
por: Pericay, Carles, et al.
Publicado: (2023)

Cardiovascular adverse effects of lopinavir/ritonavir and hydroxychloroquine in COVID-19 patients: Cases from a single pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database
por: Revet, Alexis, et al.
Publicado: (2020)

Editorial: Real world evidence, outcome research and healthcare management improvement through real world data (RWD)
por: Varela-Rodríguez, Carolina, et al.
Publicado: (2023)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Pharmacovigilance training with focus on India
por: Olsson, Sten
Publicado: (2008)

PIN65 Socio-Economic Burden of COVID-19 in Russian Federation
por: Kolbin, A., et al.
Publicado: (2020)

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada
por: Ali, Thibault B., et al.
Publicado: (2015)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

RWD26 Real World Evidence for the Impact of COVID-19 Pandemic on the Incidence of Multiple Myeloma in Germany
por: Schilling, S, et al.
Publicado: (2022)

PDG17 Adverse Drug Reactions Associated to Hydroxychloroquine and Remdesivir in COVID-19 Patients: Analysis of Reported ADR to the Portuguese Pharmacovigilance System
por: Ivos, R., et al.
Publicado: (2021)

RWD152 Real-World Evidence on the Use of Ecmo in Hospitalized COVID-19 Patients: Results from a Linked Closed and Open Claims Database in the US
por: Kuranz, S., et al.
Publicado: (2023)

Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database
por: Nguyen, Lee S., et al.
Publicado: (2022)

Potential and Pitfalls of Pharmacovigilance Databases in Oncology
por: Schlam, Ilana, et al.
Publicado: (2023)

Serious Cardiovascular Adverse Events Associated with Hydroxychloroquine/Chloroquine Alone or with Azithromycin in Patients with COVID-19: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS)
por: Zhao, Ying, et al.
Publicado: (2022)

Safety of Anthroposophic Medicinal Products: An Analysis of Adverse Drug Reactions from German Pharmacovigilance Databases
por: Jong, Miek C., et al.
Publicado: (2021)

Adverse Drug Reactions with Drugs Used in Multiple Sclerosis: An Analysis from the Italian Pharmacovigilance Database
por: Barbieri, Maria Antonietta, et al.
Publicado: (2022)

Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database
por: Hoisnard, Léa, et al.
Publicado: (2022)

Adverse Drug Reactions and Potentially Inappropriate Medication in Older Patients: Analysis of the Portuguese Pharmacovigilance Database
por: Gomes, Daniel, et al.
Publicado: (2022)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

RWD33 Analysis of COVID-19 Vaccine-Related Adverse Events in Adults, Geriatrics and Pediatrics – A Retrospective Study
por: Roy, A, et al.
Publicado: (2022)

Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database
por: Sato, Kenichiro, et al.
Publicado: (2021)

The Russian Bioimpedance Database: An Update
por: Rudnev, Sergey G., et al.
Publicado: (2022)

Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation
por: Ozcan, Gulnihal, et al.
Publicado: (2016)

Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database
por: Ruggiero, Rosanna, et al.
Publicado: (2020)

A Sex- and Gender-Based Analysis of Adverse Drug Reactions: A Scoping Review of Pharmacovigilance Databases
por: Brabete, Andreea C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_o0s2j0kvjo140v3eppa2mud29t